Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Document Type
Year range
1.
International Journal of the Cardiovascular Academy ; 8(1):20-23, 2022.
Article in English | EMBASE | ID: covidwho-1792242

ABSTRACT

Introduction: Patients receiving anticoagulant therapy experience a serious problem at a time when the rates of outpatient visits for the international normalized ratio (INR) monitoring are gradually decreasing owing to the risk of virus transmission during the pandemic. The aim of this multicenter study was to investigate how the coronavirus disease 2019 pandemic affected the time in therapeutic range (TTR) value, which shows the use of effective doses of warfarin, and its monitoring in patients using warfarin. Materials and Methods: A total of 158 patients with 3 consecutive prepandemic INR levels and at least 3 postpandemic INR levels without time limitation were retrospectively evaluated. TTR values were calculated and the preepidemic and postepidemic values were compared. TTR was obtained using the conventional method. Results: The mean preepidemic and postepidemic TTR values were found to be 64.4 (61.8%-67.0%) and 34.9 (30.8%-39.0%), respectively. TTR rate was statistically significantly lower in the postpandemic period than in the prepandemic period (P < 0.001). While the prepandemic TTR of 68 (43%) patients was <60, the postpandemic TTR of 125 (79%) patients was <60. Discussion and Conclusion: Patients using warfarin were found to have lower TTR values during the pandemic. One of the most important reasons for this result is patients' delayed admission to the hospital due to fear of infection. The importance of regular follow-ups and alternative solutions should be emphasized for the effective treatment of these patients.

2.
Acta Virol ; 64(4): 389-395, 2020.
Article in English | MEDLINE | ID: covidwho-993907

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused fatal outbreaks of pneumonia. The similarity of S protein of SARS-CoV-2 with SARS-CoV and RaTG13 is about 76% and 97%, respectively. Also its potential receptor-binding domain (RBD) shows similarity with approximately 74% and 90.1% for SARS-CoV and RaTG13, respectively. SARS-CoV-2 has been shown to use the SARS-CoV receptor ACE2 for entry and serine protease TMPRSS2 for S protein priming. Sialic acids are primarily expressed by vertebrates and some microbial pathogens improving the ability to avoid immune system of vertebrate host. Interactions of sialic acid-binding Ig-like lectins (Siglecs) with their ligands play an important role in modulating immune cell function activities as their regulators. Therefore, while Siglecs help immune cells to distinguish between self and non-self, non-self ligands of some sialylated pathogens can recognize Siglecs and reduce immune cell responses or escape from immune surveillance. In this review, innate immunity in SARS-Cov-2 infection was discussed through Siglecs, especially Siglec-7, Siglec-3, NKG2A and neuraminidases. Keywords: SARS-Cov-2; siglecs; NK cells; NKG2A; neuraminidases.


Subject(s)
COVID-19/immunology , Immunity, Innate , Immunotherapy , Sialic Acid Binding Immunoglobulin-like Lectins/immunology , Animals , Humans , SARS-CoV-2 , Sialic Acids , Spike Glycoprotein, Coronavirus/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL